The relationship between hyperuricemia and hypertension: a short review of current evidence

Abstract

The investigation of the relationship between hyperuricemia and hypertension is a captivating field in hypertension research. The final product of purine metabolism is uric acid (UA), and the elevation of serum UA (SUA) levels directly contributes to the development of hypertension. Numerous studies have substantiated that hyperuricemia is a significant risk factor for hypertension. Furthermore, initial clinical trials have demonstrated that therapeutic interventions aimed at reducing SUA levels lower blood pressure (BP) in individuals with hypertension attributed to hyperuricemia. Recent research has demonstrated that hyperuricemia can facilitate the onset of hypertension via multiple mechanisms, including oxidative stress, inflammation, diminished nitric oxide (NO) synthesis, activation of reactive oxygen species (ROS), insulin resistance, vascular smooth muscle proliferation, and renal impairment. Given the interconnectedness between hyperuricemia and hypertension, it is advantageous to identify potential therapeutic approaches for timely intervention in order to impede the advancement of hypertension in individuals with hyperuricemia. This article reviews the research progress on the pathogenesis of hyperuricemia-induced hypertension.

Keywords

Hyperuricemia / hypertension / blood pressure / mechanisms / research progress / review

References

[1] Zhu Y,Choi HK.Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008.Arthritis Rheum2011;63:3136-41

[2] Gaubert M,Cohen-Solal A.Hyperuricemia and hypertension, coronary artery disease, kidney disease: from concept to practice.Int J Mol Sci2020;21:4066. PMCID:PMC7312288

[3] Ali N,Islam F.Relationship between serum uric acid and hypertension: a cross-sectional study in Bangladeshi adults.Sci Rep2019;9:9061. PMCID:PMC6588567

[4] The Lancet. NICE hypertension guidelines: a pragmatic compromise.Lancet2019;394:806

[5] Mahomed FA.On chronic bright’s disease, and its essential symptoms.Lancet1879;113:399-401

[6] Cao Z,Li S.Mediation of the effect of serum uric acid on the risk of developing hypertension: a population-based cohort study.J Transl Med2019;17:202. PMCID:PMC6582569

[7] Feig DI.The role of uric acid in the pathogenesis of hypertension in the young.J Clin Hypertens2012;14:346-52 PMCID:PMC8108870

[8] Grayson PC,LaValley M.Hyperuricemia and incident hypertension: a systematic review and meta-analysis.Arthritis Care Res2011;63:102-10. PMCID:PMC3016454

[9] Yokokawa H,Suzuki A.Association between serum uric acid levels/hyperuricemia and hypertension among 85,286 Japanese workers.J Clin Hypertens (Greenwich)2016;18:53-9 PMCID:PMC8031541

[10] Fayemi OB,Bolaji OB.Relationship between serum uric acid and hypertension among secondary school adolescents in Ekiti State, Nigeria.West Afr J Med2023;40:997-1002

[11] Feig DI,Karumanchi SA.Hypothesis: uric acid, nephron number, and the pathogenesis of essential hypertension.Kidney Int2004;66:281-7.

[12] Feig DI,Johnson RJ.Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial.JAMA2008;300:924-32 PMCID:PMC2684336

[13] Ubhadiya TJ,Sojitra MH.Exploring the effects of elevated serum uric acid levels on hypertension: a scoping review of hyperuricemia.Cureus2023;15:e43361 PMCID:PMC10494276

[14] Sautin YY.Uric acid: the oxidant-antioxidant paradox.Nucleosides Nucleotides Nucleic Acids2008;27:608-19 PMCID:PMC2895915

[15] Huang Z,Zhang X.Aldose reductase mediates endothelial cell dysfunction induced by high uric acid concentrations.Cell Commun Signal2017;15:3. PMCID:PMC5217275

[16] Sánchez-Lozada LG,Cristóbal-García M.Uric acid-induced endothelial dysfunction is associated with mitochondrial alterations and decreased intracellular ATP concentrations.Nephron Exp Nephrol2012;121:e71-8. PMCID:PMC3656428

[17] Kimura Y,Kono H.Uric acid in inflammation and the pathogenesis of atherosclerosis.Int J Mol Sci2021;22:12394 PMCID:PMC8624633

[18] Sanchez-Lozada LG,Kelley EE.Uric acid and hypertension: an update with recommendations.Am J Hypertens2020;33:583-94. PMCID:PMC7368167

[19] Sánchez-Lozada LG,Soto V.Treatment with the xanthine oxidase inhibitor febuxostat lowers uric acid and alleviates systemic and glomerular hypertension in experimental hyperuricaemia.Nephrol Dial Transplant2008;23:1179-85.

[20] Vermot A,Smith SME.NADPH oxidases (NOX): an overview from discovery, molecular mechanisms to physiology and pathology.Antioxidants2021;10:890 PMCID:PMC8228183

[21] Kimura Y,Onda A,Hosoyamada M.Soluble uric acid promotes atherosclerosis via AMPK (AMP-activated protein kinase)-mediated inflammation.Arterioscler Thromb Vasc Biol2020;40:570-82

[22] Kuwabara M.Hyperuricemia, cardiovascular disease, and hypertension.Pulse2016;3:242-52 PMCID:PMC4865070

[23] Ruggiero C,Ble A.Uric acid and inflammatory markers.Eur Heart J2006;27:1174-81 PMCID:PMC2668163

[24] Kırça M,Çetin A,Yeşilkaya A.Uric acid stimulates proliferative pathways in vascular smooth muscle cells through the activation of p38 MAPK, p44/42 MAPK and PDGFRβ.J Recept Signal Transduct Res2017;37:167-73

[25] Li Z,Chen Y,Cheng J.High uric acid inhibits cardiomyocyte viability through the ERK/P38 pathway via oxidative stress.Cell Physiol Biochem2018;45:1156-64

[26] Cordero MD,Ryffel B.AMP-activated protein kinase regulation of the nlrp3 inflammasome during aging.Trends Endocrinol Metab2018;29:8-17.

[27] Crişan TO,Novakovic B.Uric acid priming in human monocytes is driven by the AKT-PRAS40 autophagy pathway.Proc Natl Acad Sci U S A2017;114:5485-90 PMCID:PMC5448210

[28] Zhao Y,Sun Z.Role of PI3K in the progression and regression of atherosclerosis.Front Pharmacol2021;12:632378 PMCID:PMC7985550

[29] Liang WY,Zhang JW,Wang YC.Uric acid promotes chemokine and adhesion molecule production in vascular endothelium via nuclear factor-kappa B signaling.Nutr Metab Cardiovasc Dis2015;25:187-94

[30] Feig DI.Serum uric acid and the risk of hypertension and chronic kidney disease.Curr Opin Rheumatol2014;26:176-85

[31] Dhanasekar C,Rasool M.Morin, a bioflavonoid suppresses monosodium urate crystal-induced inflammatory immune response in RAW 264.7 macrophages through the inhibition of inflammatory mediators, intracellular ROS levels and NF-κB activation.PLoS One2015;10:e0145093 PMCID:PMC4692533

[32] Xiao J,Fu C.Soluble uric acid increases NALP3 inflammasome and interleukin-1β expression in human primary renal proximal tubule epithelial cells through the toll-like receptor 4-mediated pathway.Int J Mol Med2015;35:1347-54.

[33] Crouch SH,Delles C,Schutte AE.Inflammation and hypertension development: a longitudinal analysis of the African-PREDICT study.Int J Cardiol Hypertens2020;7:100067 PMCID:PMC7768897

[34] Hong FF,Liu W.Roles of eNOS in atherosclerosis treatment.Inflamm Res2019;68:429-41

[35] Wei X,Huang S.Hyperuricemia: a key contributor to endothelial dysfunction in cardiovascular diseases.FASEB J2023;37:e23012.

[36] Caldwell RW,Toque HA,Caldwell RB.Arginase: a multifaceted enzyme important in health and disease.Physiol Rev2018;98:641-65. PMCID:PMC5966718

[37] Papežíková I,Kolářová H.Uric acid modulates vascular endothelial function through the down regulation of nitric oxide production.Free Radic Res2013;47:82-8

[38] Watanabe T,Abe K.Increased lung uric acid deteriorates pulmonary arterial hypertension.J Am Heart Assoc2021;10:e022712 PMCID:PMC9075373

[39] Kolluru GK,Chatterjee S.eNOS phosphorylation in health and disease.Biochimie2010;92:1186-98

[40] Park JH,Hwang S,Kang DH.Uric acid attenuates nitric oxide production by decreasing the interaction between endothelial nitric oxide synthase and calmodulin in human umbilical vein endothelial cells: a mechanism for uric acid-induced cardiovascular disease development.Nitric Oxide2013;32:36-42.

[41] Li P,Zhang M,Lin N.Uric acid enhances PKC-dependent eNOS phosphorylation and mediates cellular ER stress: A mechanism for uric acid-induced endothelial dysfunction.Int J Mol Med2016;37:989-97 PMCID:PMC4790645

[42] Gersch C,Kim KM,Johnson RJ.Inactivation of nitric oxide by uric acid.Nucleosides Nucleotides Nucleic Acids2008;27:967-78 PMCID:PMC2701227

[43] Ames MK,Pitt B.The renin-angiotensin-aldosterone system and its suppression.J Vet Intern Med2019;33:363-82 PMCID:PMC6430926

[44] Yu MA,Johnson RJ.Oxidative stress with an activation of the renin-angiotensin system in human vascular endothelial cells as a novel mechanism of uric acid-induced endothelial dysfunction.J Hypertens2010;28:1234-42.

[45] Mazzali M,Han L.Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism.Am J Physiol Renal Physiol2002;282:F991-7

[46] Corry DB,Yamamoto K,Makino H.Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular renin-angiotensin system.J Hypertens2008;26:269-75

[47] Li K,Yao Q.The potential relationship of coronary artery disease and hyperuricemia: a cardiometabolic risk factor.Heliyon2023;9:e16097 PMCID:PMC10199191

[48] Yu P,Wang Z,Yu X.The association of serum uric acid with beta-cell function and insulin resistance in nondiabetic individuals: a cross-sectional study.Diabetes Metab Syndr Obes2021;14:2673-82 PMCID:PMC8214016

[49] Choi HK.Haemoglobin A1c, fasting glucose, serum C-peptide and insulin resistance in relation to serum uric acid levels--the Third National Health and Nutrition Examination Survey.Rheumatology2008;47:713-7

[50] Niu Y,Zhao X.Obesity-induced insulin resistance is mediated by high uric acid in obese children and adolescents.Front Endocrinol2021;12:773820. PMCID:PMC8678632

[51] Choi YJ,Lee KY.Uric acid induces endothelial dysfunction by vascular insulin resistance associated with the impairment of nitric oxide synthesis.FASEB J2014;28:3197-204

[52] Tassone EJ,Perticone M.Uric acid impairs insulin signaling by promoting enpp1 binding to insulin receptor in human umbilical vein endothelial cells.Front Endocrinol2018;9:98 PMCID:PMC5879120

[53] Han T,Qu R.Temporal relationship between hyperuricemia and insulin resistance and its impact on future risk of hypertension.Hypertension2017;70:703-11.

[54] Wan X,Lin Y.Uric acid regulates hepatic steatosis and insulin resistance through the NLRP3 inflammasome-dependent mechanism.J Hepatol2016;64:925-32.

[55] Takir M,Ozkok A.Lowering uric acid with allopurinol improves insulin resistance and systemic inflammation in asymptomatic hyperuricemia.J Investig Med2015;63:924-9

[56] Mazzali M,Kim YG.Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism.Hypertension2001;38:1101-6.

[57] Cristóbal-García M,Tapia E.Renal oxidative stress induced by long-term hyperuricemia alters mitochondrial function and maintains systemic hypertension.Oxid Med Cell Longev2015;2015:535686 PMCID:PMC4396880

[58] Sánchez-Lozada LG,Santamaría J.Mild hyperuricemia induces vasoconstriction and maintains glomerular hypertension in normal and remnant kidney rats.Kidney Int2005;67:237-47

[59] Romi MM,Tranggono U,Sari DCR.Uric acid causes kidney injury through inducing fibroblast expansion, Endothelin-1 expression, and inflammation.BMC Nephrol2017;18:326 PMCID:PMC5664905

[60] Ma H,Guo X,Qi L.Distinct uric acid trajectories are associated with different risks of incident hypertension in middle-aged adults.Mayo Clin Proc2019;94:611-9

[61] Zhao H,Lu Y.The potential of probiotics in the amelioration of hyperuricemia.Food Funct2022;13:2394-414

[62] Robles-Vera I,de la Visitación N.Probiotics prevent dysbiosis and the rise in blood pressure in genetic hypertension: role of short-chain fatty acids.Mol Nutr Food Res2020;64:e1900616

[63] Li Y,Yu C,Miao M.Association of serum uric acid level with non-alcoholic fatty liver disease: a cross-sectional study.J Hepatol2009;50:1029-34.

[64] Sun Q,Manji L.Association between serum uric acid and non-alcoholic fatty liver disease: an updated systematic review and meta-analysis.Clin Epidemiol2023;15:683-93 PMCID:PMC10252946

[65] Ryoo JH,Shin HC,Choi JM.Clinical association between non-alcoholic fatty liver disease and the development of hypertension.J Gastroenterol Hepatol2014;29:1926-31

[66] Zhao YC,Chen Z,Cai J.Nonalcoholic fatty liver disease: an emerging driver of hypertension.Hypertension2020;75:275-84

[67] Mori K,Hosaka I.Metabolic dysfunction-associated fatty liver disease is associated with an increase in systolic blood pressure over time: linear mixed-effects model analyses.Hypertens Res2023;46:1110-21

[68] Abbasi S,Jadoon S.Association Of non-alcoholic fatty liver disease with serum uric acid.J Ayub Med Coll Abbottabad2019;31:64-6.

[69] Assadi F.Allopurinol enhances the blood pressure lowering effect of enalapril in children with hyperuricemic essential hypertension.J Nephrol2014;27:51-6.

[70] Beattie CJ,Higgins P.Allopurinol initiation and change in blood pressure in older adults with hypertension.Hypertension2014;64:1102-7.

[71] Gill D,Burgess S.VA Million Veteran ProgramUrate, blood pressure, and cardiovascular disease: evidence from mendelian randomization and meta-analysis of clinical trials.Hypertension2021;77:383-92 PMCID:PMC7803439

[72] Borghi C,Cicero AFG,Virdis A.Uric acid and hypertension: a review of evidence and future perspectives for the management of cardiovascular risk.Hypertension2022;79:1927-36